Discontinuing Psychotropic Drugs from Participants in Randomized Controlled Trials: A Systematic Review
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Background and Objective: Methods and justifications for discontinuing psychotropic drugs in randomized controlled trials (RCTs), and RCTs’ acknowledgement of possible withdrawal symptoms following discontinuation, have not been examined systematically, which this review aims to do. Study Eligibility, Data Extraction, and Synthesis: Publications in MEDLINE, EMBASE, and PsycINFO (2000–2017) randomly assigning participants diagnosed with mental disorders to discontinue antipsychotic, antidepressant, anticonvulsant, antimanic, mood-stabilizing, benzodiazepine, or stimulant drugs. Authors independently extracted data, devised a typology of trials, and assessed trials’ recognition of withdrawal symptoms. Results: Eighty RCTs (70% with industry participation) discontinued drugs from 5,757 participants to investigate relapse prevention (44%), successful discontinuation (26%), architecture of withdrawal (14%), and practicality of discontinuation (10%). RCTs of stimulants, antidepressants, and antipsychotics mostly aimed to reach conclusions about relapse prevention by testing abrupt or rapid discontinuations; RCTs of benzodiazepines mostly aimed to reduce drug use by testing longer-lasting, supportive discontinuations. In 67% of RCTs, no justification was given for the specific discontinuation strategy, which lasted under 2 weeks in 60% of RCTs. Possible withdrawal confounding of trial outcomes was addressed in 14% of eligible RCTs. Limitations: Only the published literature was searched. Conclusions and Implications: RCTs use drug discontinuation to study several key issues in psychopharmacology but infrequently justify how they implement it or acknowledge that possible withdrawal symptoms may threaten internal validity. Reappraising the use of drug discontinuation and the recognition of withdrawal symptoms in RCTs is required.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although none of the trials on which this conclusion was based measured withdrawal effects (Cohen 2019;Hengartner 2020;Recalt 2019)”
From Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults (2021) · cites this paper as Cohen 2019
In the citing paper
“Like all other pharmacological agents used in medicine, psychotropic medications discontinuation can induce withdrawal syndromes but not all psychotropic medications are the same between classes and within a class [13, 181].”
From Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) · cites this paper as [181]
In the citing paper
“we have no way to know how many of the relapses were actually withdrawal and post-withdrawal syndromes in the group that underwent drug tapering and discontinuation.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [66]
In the citing paper
“The evidence supporting this strategy, however, is based mainly on clinical trials where remitted patients were randomized to drug continuation or placebo, without any differentiation between withdrawal and relapse.”
From May antidepressant drugs worsen the conditions they are supposed to treat? The clinical foundations of the oppositional model of tolerance (2020) · cites this paper as [66]
Citations
Cites
Fava, G. A., Gatti, A., Belaise, C., Guidi, J., & Offidani, E. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000370338 · Cited by 436
Neuroleptic Withdrawal in Schizophrenic Patients: A Review of the Literature
Gilbert, P. L. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150005001 · Cited by 435
Perlis, R. H., Perlis, C. S., Wu, Y., Hwang, C., Joseph, M., & Nierenberg, A. A. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.10.1957 · Cited by 318
Antidepressant discontinuation reactions: Are preventable and simple to treat
Haddad, P., Lejoyeux, M., & Young, A. (1998) · BMJ · doi:10.1136/bmj.316.7138.1105 · Cited by 286
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy
Chouinard, G., Samaha, A.-N., Chouinard, V.-A., Peretti, C.-S., Kanahara, N., Takase, M., & Iyo, M. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000477313 · Cited by 270
Neuroleptic-induced supersensitivity psychosis
(1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.11.1409 · Cited by 224
Frances, R. J. (2007) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70411-0 · Cited by 220
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Neuroleptic Withdrawal in Schizophrenic Patients
Baldessarini, R. J. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950150021002 · Cited by 195
CURRAN, H. V., COLLINS, R., FLETCHER, S., KEE, S. C. Y., WOODS, B., & ILIFFE, S. (2003) · Psychological Medicine · doi:10.1017/s0033291703008213 · Cited by 190
Endocrine withdrawal syndromes
Hochberg, Z., Pacak, K., & Chrousos, G. P. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0014 · Cited by 181
Chouinard, G., & Chouinard, V.-A. (2008) · Psychotherapy and Psychosomatics · doi:10.1159/000112883 · Cited by 168
New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal
Chouinard, G., & Chouinard, V.-A. (2015) · Psychotherapy and Psychosomatics · doi:10.1159/000371865 · Cited by 164
(1997) · PubMed · Cited by 149
Reducing antipsychotic medication in people with a learning disability
Ahmed, M. Z., Fraser, W., Kerr, M., Kiernan, C., Emerson, E., Robertson, J., Felce, D., Allen, D. G., Baxter, H., & Thomas, J. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.176.1.42 · Cited by 145
Ballard, C. G., Thomas, A., Fossey, J., Lee, L., Jacoby, R., Lana, M. M., Bannister, C., McShane, R., Swann, A., Juszczak, E., et al. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0120 · Cited by 141
The SSRI discontinuation syndrome
Haddad, P. (1998) · Journal of Psychopharmacology · doi:10.1177/026988119801200311 · Cited by 126
Illness risk following rapid versus gradual discontinuation of antidepressants
Baldessarini, R. J., Tondo, L., Ghiani, C., & Lepri, B. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.09060880 · Cited by 123
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
Nielsen, M., Hansen, E. H., & Gøtzsche, P. C. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03686.x · Cited by 103
A review of the management of antidepressant discontinuation symptoms
Wilson, E., & Lader, M. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125315612334 · Cited by 103
Escitalopram for Compulsive Buying Disorder: A Double-Blind Discontinuation Study
Koran, L. M., Aboujaoude, E. N., Solvason, B., Gamel, N. N., & Smith, E. H. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000264975.79367.f4 · Cited by 100
Koesters, M., Guaiana, G., Cipriani, A., Becker, T., & Barbui, C. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.120196 · Cited by 93
A Prescription for “Deprescribing” in Psychiatry
Gupta, S., & Cahill, J. D. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201500359 · Cited by 84
Ruths, S., Straand, J., Nygaard, H. A., & Aarsland, D. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1998 · Cited by 83
Antidepressant Withdrawal Syndromes: Phenomenology and Pathophysiology
DILSAVER, S. C., GREDEN, J. F., & SNIDER, R. M. (1987) · International Clinical Psychopharmacology · doi:10.1097/00004850-198701000-00001 · Cited by 81
de Kuijper, G. M., Evenhuis, H. M., Minderaa, R. B., & Hoekstra, P. J. (2012) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2012.01631.x · Cited by 79
Hypnotic taper with or without self-help treatment of insomnia: A randomized clinical trial.
Belleville, G., Guay, C., Guay, B., & Morin, C. M. (2007) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.75.2.325 · Cited by 77
Discontinuing Antidepressant Drugs: Lesson from a Failed Trial and Extensive Clinical Experience
Fava, G. A., & Belaise, C. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000492693 · Cited by 77
van Reekum, R., Conn, D., Clarke, D., Cohen, T., Ostrander, L., Herrmann, N., & Eryavec, G. (2002) · International Psychogeriatrics · doi:10.1017/s1041610202008396 · Cited by 74
TERMINATION OF CHLORPROMAZINE WITH SCHIZOPHRENIC PATIENTS
GOOD, W. W., STERLING, M., & Holtzman, W. H. (1958) · American Journal of Psychiatry · doi:10.1176/ajp.115.5.443 · Cited by 73
WITHDRAWAL FROM NEUROLEPTIC DRUGS
Brooks, G. W. (1959) · American Journal of Psychiatry · doi:10.1176/ajp.115.10.931 · Cited by 73
The Benzodiazepines – for Good or Evil
Marks, J. (1983) · Neuropsychobiology · doi:10.1159/000117997 · Cited by 70
Publication Bias, with a Focus on Psychiatry: Causes and Solutions
Turner, E. H. (2013) · CNS Drugs · doi:10.1007/s40263-013-0067-9 · Cited by 70
Discontinuing Psychiatric Medications: A Survey of Long-Term Users
Ostrow, L., Jessell, L., Hurd, M., Darrow, S. M., & Cohen, D. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201700070 · Cited by 62
Self-citationSchatzberg, A. F., Haddad, P. M., Kaplan, E. M., Lejoyeux, M., Rosenbaum, J. F., Young, A. H., & Zajecka, J. (1997) · PubMed · Cited by 61
Why is it so difficult to stop psychiatric drug treatment?
Moncrieff, J. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.03.009 · Cited by 59
Huijbers, M. J., Spinhoven, P., Spijker, J., Ruhé, H. G., van Schaik, D. J. F., van Oppen, P., Nolen, W. A., Ormel, J., Kuyken, W., van der Wilt, G. J., et al. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.168971 · Cited by 58
Coghill, D. R., Banaschewski, T., Lecendreux, M., Johnson, M., Zuddas, A., Anderson, C. S., Civil, R., Dauphin, M., Higgins, N., Lyne, A., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.01.017 · Cited by 57
Arnold, L. E., Lindsay, R. L., Conners, C. K., Wigal, S. B., Levine, A. J., Johnson, D. E., West, S. A., Sangal, R. B., Bohan, T. P., & Zeldis, J. B. (2004) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2004.14.542 · Cited by 51
Cortese, L., Caligiuri, M. P., Williams, R., Schieldrop, P., Manchanda, R., Malla, A., & Harricharan, R. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318160864f · Cited by 47
Guidance for the discontinuation or switching of antidepressant therapies in adults
Ogle, N. R., & Akkerman, S. R. (2013) · Journal of Pharmacy Practice · doi:10.1177/0897190012467210 · Cited by 45
Brams, M., Weisler, R., Findling, R. L., Gasior, M., Hamdani, M., Ferreira-Cornwell, M. C., & Squires, L. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07430 · Cited by 41
Récalt, A. M., & Cohen, D. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496734 · Cited by 38
Self-citationInternational Task Force on Benzodiazepines
Balon, R., Chouinard, G., Cosci, F., Dubovsky, S. L., Fava, G. A., Freire, R. C., Greenblatt, D. J., Krystal, J. H., Nardi, A. E., Rickels, K., et al. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000489538 · Cited by 35
Addictiveness of Central Stimulants
Dackis, C. A., & Gold, M. S. (1990) · Advances in Alcohol & Substance Abuse · doi:10.1300/j251v09n01_02 · Cited by 34
Postpartum Depression Recurrence Versus Discontinuation Syndrome
Sunder, K. R., Wisner, K. L., Hanusa, B. H., & Perel, J. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0916 · Cited by 17
Discontinuing psychotropic agents
Baldessarini, R. J., Viguera, A. C., & Tondo, L. (1999) · Journal of Psychopharmacology · doi:10.1177/026988119901300314 · Cited by 16
[Taperingstrips for paroxetine and venlafaxine].
Groot, P. C. (2013) · PubMed · Cited by 12
Kennedy, S. H., Giacobbe, P., Placenza, F. M., Hudson, C. J., Seeman, P. M., & Seeman, M. V. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.04.014 · Cited by 9
Cited by
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications
Cosci, F., & Chouinard, G. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000506868 · Cited by 265
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Fava, G. A. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320970325 · Cited by 84
Récalt, A. M., & Cohen, D. (2019) · Psychotherapy and Psychosomatics · doi:10.1159/000496734 · Cited by 38
Self-citationHengartner, M. P., & Plöderl, M. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211032051 · Cited by 23
Metadata
- Authors
- Cohen, D., & Recalt, A.
- Affiliations
- University of California, Los Angeles (US)
- Venue
- Psychotherapy and Psychosomatics
- Publisher
- S. Karger AG
- Published
- 2019
- Volume
- 88
- Issue
- 2
- Pages
- 96-104
- ISSN
- 0033-3190 (ISSN-L)
- 1423-0348
- OpenAlex
- W2935208816
- Semantic Scholar
- c818b74dc06959f0cbd925190173fb6b9fe6b334
- Cited by
- 28
- References
- 50
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2022: 2 · 2021: 8 · 2020: 5 · 2019: 4
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Psychotherapy and Psychosomatics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Ethics in Clinical Research
- Keywords
- drug discontinuation, psychotropic drugs, withdrawal symptoms, antipsychotic drugs, antidepressants, benzodiazepines, stimulants, relapse prevention, internal validity, confounding, mental illness, randomized controlled trials
- MeSH terms
- Mental Disorders, Humans, Psychotropic Drugs, Substance Withdrawal Syndrome, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.